The authors reply

New England Journal of Medicine

Volumn 373, Issue 18, 2015, Pages 1783-1784

  Wainwright, Claire E ^a   Elborn, J Stuart ^b   Ramsey, Bonnie W ^c  

^a LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DORNASE ALFA; IVACAFTOR PLUS LUMACAFTOR; PANCREAS ENZYME; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

CFTR GENE; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG COST; FORCED EXPIRATORY VOLUME; HOMOZYGOSITY; HOSPITAL ADMISSION; HUMAN; LETTER; LUNG DISEASE; PRIORITY JOURNAL; FEMALE; GENETICS; MALE;

AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; HUMANS; MALE; QUINOLONES;

EID: 84945371575     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1510466     Document Type: Letter

References (1)

1. Elborn JS, Ramsay BW, Boyle MP, et al. Lumacaftor/ivacaftor combination therapy in CF patients homozygous for F508del CFTR with severe lung dysfunction. J Cyst Fibros 2015;14:Suppl 1:S94. abstract.